Phase II study of pegylated liposomal doxorubicin (Caelyx) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy.

Trial Profile

Phase II study of pegylated liposomal doxorubicin (Caelyx) in breast cancer patients with brain metastases and not candidate for an antiHER2 therapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2012

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms AROBASE
  • Most Recent Events

    • 04 Jul 2012 Merck and Co added as associations as reported in the European Clinical Trials Database record.
    • 10 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top